Theradiag SA (ALTHE) - Total Assets
Based on the latest financial reports, Theradiag SA (ALTHE) holds total assets worth €11.55 Million EUR (≈ $13.50 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Theradiag SA (ALTHE) shareholders funds for net asset value and shareholders' equity analysis.
Theradiag SA - Total Assets Trend (2001–2024)
This chart illustrates how Theradiag SA's total assets have evolved over time, based on quarterly financial data.
Theradiag SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Theradiag SA's total assets of €11.55 Million consist of 72.1% current assets and 27.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 36.4% |
| Accounts Receivable | €446.66K | 3.9% |
| Inventory | €2.11 Million | 18.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.13 Million | 9.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how Theradiag SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALTHE company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theradiag SA's current assets represent 72.1% of total assets in 2024, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 36.4% of total assets in 2024, up from 11.3% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is inventory at 18.4% of total assets.
Theradiag SA Competitors by Total Assets
Key competitors of Theradiag SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
Theradiag SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.40 | 3.05 | 1.17 |
| Quick Ratio | 1.79 | 2.27 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €4.87 Million | €8.32 Million | €1.05 Million |
Theradiag SA - Advanced Valuation Insights
This section examines the relationship between Theradiag SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.21 |
| Latest Market Cap to Assets Ratio | 2.89 |
| Asset Growth Rate (YoY) | -38.6% |
| Total Assets | €11.47 Million |
| Market Capitalization | $33.15 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Theradiag SA's assets at a significant premium (2.89x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Theradiag SA's assets decreased by 38.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Theradiag SA (2001–2024)
The table below shows the annual total assets of Theradiag SA from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €11.47 Million ≈ $13.41 Million |
-38.56% |
| 2023-12-31 | €18.66 Million ≈ $21.82 Million |
+33.85% |
| 2022-12-31 | €13.94 Million ≈ $16.30 Million |
+17.86% |
| 2021-12-31 | €11.83 Million ≈ $13.83 Million |
+12.18% |
| 2020-12-31 | €10.55 Million ≈ $12.33 Million |
+0.31% |
| 2019-12-31 | €10.51 Million ≈ $12.29 Million |
+9.91% |
| 2018-12-31 | €9.56 Million ≈ $11.18 Million |
-30.53% |
| 2017-12-31 | €13.77 Million ≈ $16.10 Million |
-6.43% |
| 2016-12-31 | €14.71 Million ≈ $17.20 Million |
+58.96% |
| 2015-12-31 | €9.26 Million ≈ $10.82 Million |
+11.74% |
| 2014-12-31 | €8.28 Million ≈ $9.69 Million |
+181.31% |
| 2013-12-31 | €2.94 Million ≈ $3.44 Million |
-7.87% |
| 2012-12-31 | €3.20 Million ≈ $3.74 Million |
+38.53% |
| 2011-12-31 | €2.31 Million ≈ $2.70 Million |
-40.99% |
| 2010-12-31 | €3.91 Million ≈ $4.57 Million |
-40.53% |
| 2009-12-31 | €6.58 Million ≈ $7.69 Million |
+4283.33% |
| 2001-12-31 | €150.00K ≈ $175.37K |
-- |
About Theradiag SA
Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize imag… Read more